Takeda’s plans to bring back parathyroid hormone injection hit by regulatory setback in U.S

Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I

jetcityimage/iStock Editorial via Getty Images

  • Takeda (NYSE:TAK) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its Prior Approval Supplement (PAS) for NATPARA (parathyroid hormone) for Injection.
  • A PAS is

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.